Back to Search
Start Over
Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients.
- Source :
-
BioMed research international [Biomed Res Int] 2022 Jan 07; Vol. 2022, pp. 1522426. Date of Electronic Publication: 2022 Jan 07 (Print Publication: 2022). - Publication Year :
- 2022
-
Abstract
- Several therapeutic regimens for COVID-19 have been studied, such as combination antiviral therapies. We aimed to compare outcome of two types of combination therapies atazanavir/ritonavir (ATV/r) or lopinavir/ritonavir (LPV/r) plus hydroxychloroquine among COVID-19 patients. 108 patients with moderate and severe forms of COVID-19 were divided into two groups (each group 54 patients). One group received ATV/r plus hydroxychloroquine, and the other group received hydroxychloroquine plus LPV/r. Then, both groups were evaluated and compared for clinical symptoms, recovery rates, and complications of treatment regimens. Our findings showed a significant increase in bilirubin in ATV/r-receiving group compared to LPV/r receivers. There was also a significant increase in arrhythmias in the LPV/r group compared to the ATV/r group during treatment. Other findings including length of hospital stay, outcome, and treatment complications were not statistically significant. There is no significant difference between protease inhibitor drugs including ATV/r and LPV/r in the treatment of COVID-19 regarding clinical outcomes. However, some side effects such as hyperbilirubinemia and arrhythmia were significantly different by application of atazanavir or lopinavir.<br />Competing Interests: The authors declare no competing interests.<br /> (Copyright © 2022 Hossein Mazaherpour et al.)
- Subjects :
- Aged
Antiviral Agents therapeutic use
Arrhythmias, Cardiac chemically induced
Arrhythmias, Cardiac physiopathology
Bilirubin analysis
COVID-19 metabolism
Drug Combinations
Drug Therapy, Combination methods
Female
Hospitalization trends
Humans
Hydroxychloroquine therapeutic use
Length of Stay trends
Male
Middle Aged
SARS-CoV-2 drug effects
SARS-CoV-2 pathogenicity
Treatment Outcome
Atazanavir Sulfate therapeutic use
Lopinavir therapeutic use
Ritonavir therapeutic use
COVID-19 Drug Treatment
Subjects
Details
- Language :
- English
- ISSN :
- 2314-6141
- Volume :
- 2022
- Database :
- MEDLINE
- Journal :
- BioMed research international
- Publication Type :
- Academic Journal
- Accession number :
- 35013710
- Full Text :
- https://doi.org/10.1155/2022/1522426